COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC).

7022 Background: Selecting carboplatin or cisplatin in the treatment of poor prognosis and/or extensive stage SCLC remains controversial. We performed an IPD meta-analysis from published randomized trials. Methods: In June 2009, a systematic review was performed to identify randomized phase III trials comparing cisplatin- vs. carboplatin-based CT in the first-line treatment of SCLC. Primary endpoint of the meta-analysis was overall survival (OS). IPD (baseline characteristics, treatment details, toxicity and outcome measures) were obtained via collaborating with all groups identified by the systematic review. All statistical analyses were stratified by trials. OS and progression-free survival (PFS) curves were compared using the log-rank test. Response rate was compared using the Mantel-Haenszel test. Results: All four eligible trials were included in the analysis with a total of 663 patients (329 cisplatin, 334 carboplatin). Baseline characteristics were well balanced between arms. Median age was 67 year...